PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 17, 2026S S Korsakov Journal of Neurology and Psychiatry0 citations

The effectiveness of citicoline in the treatment of cognitive disorders

View Full Paper
OSO. A. Shavlovskaya

Key Points

  • This research examines the effectiveness of citicoline in treating different types of cognitive disorders.
  • Analyzed randomized controlled trials, systematic reviews, and meta-analyses.
  • Administered citicoline at various dosages (500 mg to 2000 mg) for different durations (3 to 18 months).
  • Focused on cognitive impairments stemming from post-stroke, chronic cerebral ischemia, and neurodegenerative diseases.
  • Citicoline was found to be highly effective in treating vascular cognitive impairments.
  • Improvement noted in cognitive function among patients with mild cognitive impairment linked to Alzheimer's and Parkinson's diseases.
  • Dosing regimens varied with condition severity and type, showing flexibility in treatment plans.

Abstract

Randomized controlled trials, systematic reviews, and meta-analyses have shown that citicoline is highly effective in the treatment of vascular cognitive impairments (CI) of various origins (post-stroke, chronic cerebral ischemia (CCI)), post-traumatic CI, mild CI in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), and in patients with age-related memory impairments. Citicoline administration regimens: 1) post-stroke CI at a dose of 1000 mg/day. for a course of 4—12 months; 2) mild CI of vascular origin at a dose of 500 mg/day for a course of 3—9 months; 3) CI against the background of CCI at a dose of 500—2000 mg, the duration of the course depends on the severity of the symptoms; 4) non-demented CI at a dose of 1000 mg/day course of 9 months; 5) mild CI against Parkinson’s disease at a dose of 1000 mg/day 12—18 months.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

O. A. Shavlovskaya (2026) studied this question.

synapsesocial.com/papers/69e1cf375cdc762e9d8581dchttps://doi.org/10.17116/jnevro2026126031136
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Citicolina: revisión farmacológica y clínica, actualización 20222022 · 90 citations
  2. 2Efficacy and Safety of DL-3-n-Butylphthalide in the Treatment of Poststroke Cognitive Impairment: A Systematic Review and Meta-Analysis2022 · 45 citations
  3. 3Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis2025 · 14 citations
  4. 4Citicoline for treating people with acute ischemic stroke2020 · 55 citations
  5. 5Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology2017 · 26 citations